Short answer
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $41M (up 5.5% year over year) with net income of −$38M.
Q3 2026 key financials · XBRL
- Revenue
- $41M
- +5.5% YoY · +4.0% QoQ
- Net income
- −$38M
- +0.4% YoY · +15.4% QoQ
- Operating margin
- -91.2%
- Gross margin
- 33.2%
- EPS (diluted)
- −$0.12
- +0.0% YoY · +14.3% QoQ
Source: XBRL data from the PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) Q3 2026 10-Q on SEC EDGAR. USD.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $40.6M, up 6% YoY from $38.4M, driven by product revenue and services growth
- Gross margin 33.2% vs 41.4% YoY, with gross profit down 15% to $13.5M
- Instrument revenue up 16% to $13.9M, while consumables revenue declined 2% to $20.1M
- Operating loss $37.0M, with operating margin negative 91.2% vs negative 101.1% YoY
- Cash and investments $199.4M vs $279.5M at December 31, 2025; operating cash use $117.9M
- Outlook: consumables growth expected, but funding constraints, memory costs and tariffs remain headwinds
Risk Factors
- New asset-disposition risk: January 30, 2026 sale retained pre-closing liabilities tied to short-read sequencing technologies
- New expense-reduction risk: third-quarter 2026 workforce reductions and development cuts may disrupt operations and produce higher-than-anticipated charges
- Regulatory risk: BIOSECURE Act limits certain Chinese biotechnology equipment and services, potentially disrupting supply and commercialization
- Near-term market risk: Revio and Vega adoption may lag as customers delay capital purchases amid uncertain academic and NIH funding
- Financial risk: September 30, 2026 debt included $200.0 million due 2029 and $441.0 million due 2030 amid negative operating cash flow
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.